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monoclonal antibody), or screening for latent TB before using TNF
inhibitors.
http://dx.doi.org/10.1016/j.ijid.2016.02.153
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Cytomegalovirus
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Abstract: Cytomegalovirus (CMV) remains an important
pathogen in transplant patients. Sensitive and rapid turnaround
quantitative PCR based monitoring coupled with the availability of
effective antiviral therapy has reduced the overall burden of CMV
disease after transplantation. However, in hematopoietic stem cell
transplant (HSCT) patients, the increasing use of new donor and
stem cell sources present new challenges in the prevention and
treatment of CMV. Gastrointestinal disease is now the most com-
monend-organmanifestationofCMVinfectionafterHSCT,whereas
pneumonia remains associated with high mortality. In addition,
indirect effects of CMV infection continue to have both positive
and negative effects on outcomes after HSCT. Antivirals with novel
mechanisms of action and improved toxicity proﬁles compared to
those currently available are in late phase clinical trials. Also CMV
vaccines are in development. Despite these advances, CMV is likely
to remain a signiﬁcant pathogen in transplant recipients.
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Abstract: Lack of effective antimicrobial therapy for multidrug-
resistant organisms (MDROs) has been a growing concern
particularly due to spread of extended-spectrum beta lactamase
(ESBL) and carbapenem resistant Enteriobacteriaceae (CRE). Better
therapeutics for MDROs are needed.
Common MDROs include methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), ESBL
and CRE. Gram-positive organisms such as MRSA and VRE are sta-
ble or declining in frequency while gram-negative ESBLs and CREs
are increasing. Recent antibiotics generally focus on MRSA and
gram-positiveMDROswith few new agents effective against gram-
negative organisms. Outside of common healthcare-associated
MDROs, Gonococcus has become highly antibiotic-resistant in
many parts of the world. Furthermore, most therapy for MDROs
is intravenous and associated with a high rate of adverse effects
and burden of disease related to long courses of treatment.
New antibiotics are needed with novel mechanisms of action
against MDRO organisms, fewer side effects, less impact on the
microbiome and easier, non intravenous delivery. Studies of new
drugs need to focus on rational use with minimal duration, easiest
formof delivery and clear recognition of effects on themicrobiome.
Use of new antibiotics must be appropriate and avoid overuse.
ChoosingWisely and the growth of Antimicrobial Stewardshipmay
help appropriate use.
Finally, a new model of infectious disease management is
developing based around the microbiome. Manipulation of the
microbiome may become a mainstay for treatment of many dis-
eases. Currently, fecal transplants for C. difﬁcile are the only
approach to microbiome manipulation proven to work. Other uses
may include decolonization of MDROs from the gastrointestinal
track. Future microbiome manipulations may include targeted
microbiome changes via capsules to the GI tract and possible inoc-
ulations to the skin or mucosal surfaces. Development of ways to
manipulate the microbiome could improve treatment of infectious
disease without producing antibiotic resistance.
Development of antimicrobials active against ESBLs, and CRES
that are safe and easy to use is needed. Longer range antimicrobial
therapies will likely involve microbiome manipulation.
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The antibiotic pipeline: What can we expect?
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Abstract: Antibiotic resistance is widespread. Despite the rec-
ognized and growing need for new antibiotics, today most large
pharmaceutical companies have dropped active antibacterial drug
discovery programmes. While antibiotics are regarded as non-
proﬁtable compared to other ﬁelds, small companies—mostly
backedbypromising academicdiscoveries—are stepping in todrive
research and early clinical development in the antibiotics ﬁeld. In
the 1980s and 90s the antibiotic pipelines were satisfying the need
for improved antibiotics against the prevalent resistant strains at
that time. Currently, extensively- or pan-resistant Gram-negative
bacteria require novel antibiotics without co- and cross-resistance
to known drug classes. A few research&development programs
based on classical antibacterial compounds against Gram-negative
bacteria that bind to new targets or have a new mode of action
are in the early research phase and their potential is difﬁcult
to assess. Due to such thin discovery pipelines, attitudes have
changed and antibacterial approaches outside the mainstream
are increasingly pursued and publicly funded. These alterna-
tive methodologies range from peptides and peptidomimetics
to antibodies, prophylactic and therapeutic vaccines, adjunctive
